Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 346,680,864
  • Shares Outstanding, K 2,639,166
  • Annual Sales, $ 81,581 M
  • Annual Income, $ 15,297 M
  • 60-Month Beta 0.69
  • Price/Sales 4.22
  • Price/Cash Flow 11.97
  • Price/Book 5.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 2.00
  • Number of Estimates 6
  • High Estimate 2.02
  • Low Estimate 1.99
  • Prior Year 2.05
  • Growth Rate Est. (year over year) -2.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
127.84 +2.75%
on 07/22/19
134.10 -2.04%
on 08/13/19
-1.14 (-0.86%)
since 07/16/19
3-Month
127.84 +2.75%
on 07/22/19
144.98 -9.39%
on 06/25/19
-6.85 (-4.96%)
since 05/16/19
52-Week
121.00 +8.56%
on 12/24/18
148.99 -11.83%
on 12/04/18
-1.12 (-0.85%)
since 08/16/18

Most Recent Stories

More News
JOHNSON & JOHNSON INVESTIGATION UPDATE by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Johnson & Johnson - JNJ

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Johnson & Johnson ("J&J")...

JNJ : 131.36 (+0.63%)
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY

FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.

AZN : 44.34 (+0.36%)
MRK : 85.06 (+1.92%)
JNJ : 131.36 (+0.63%)
LLY : 110.52 (+0.26%)
RHHBY : 34.7000 (+0.41%)
PFE : 34.65 (+0.49%)
Why Is Johnson & Johnson (JNJ) Down 1.2% Since Last Earnings Report?

Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

JNJ : 131.36 (+0.63%)
Echosens Appoints Dominique Legros as Group CEO: Global Healthcare Business and Technology Expert Leads Company Growth in Chronic Liver Disease Assessment

Echosens, an innovative high-technology company offering the FibroScan family of products dedicated to assessment of chronic liver disease, announces the appointment of Dominique Legros as Group CEO, based...

JNJ : 131.36 (+0.63%)
Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study

Lilly's (LLY) Taltz is an important revenue driver for Lilly. Top-line data from a study shows that Taltz helps more plaque psoriasis patients achieve 100% skin clearance compared to Tremfya.

JNJ : 131.36 (+0.63%)
LLY : 110.52 (+0.26%)
NVS : 89.47 (+1.00%)
ABBV : 64.43 (+2.30%)
Global Breast Implants (Augmentation & Reconstruction) Markets, 2017-2018 & 2019-2023 with Profiles of Allergan,GC Aesthetics, Johnson & Johnson, Sientra

The "Global Breast Implants Market with Focus on Breast Augmentation & Breast Reconstruction: Size, Trends and Forecasts (2019-2023)" report has been added to ResearchAndMarkets.com's offering.

JNJ : 131.36 (+0.63%)
AGN : 158.25 (+1.22%)
Legal Marijuana Market Likely to Emerge over a Period of 2019 - 2024 | Medicine Man, Canopy Growth, Aphria, Aurora Cannabis Inc., mCig Inc

Legal Marijuana Market Industry Global Market Research Report 2019 report also explains information about the market size, share, company growth, regional demands, trends, and technical analysis.

ABC : 87.34 (+1.59%)
JNJ : 131.36 (+0.63%)
MRK : 85.06 (+1.92%)
CAH : 43.19 (+2.83%)
PFE : 34.65 (+0.49%)
UNH : 245.69 (+0.59%)
BMY : 46.98 (+2.69%)
ACB.TO : 7.91 (+3.67%)
MCIG : 0.0590 (-2.96%)
ABT : 84.78 (+1.00%)
MCK : 145.29 (+2.85%)
TMO : 276.15 (+1.04%)
MDT : 102.76 (+0.99%)
Global Monofocal IOLs Market 2019 Growth, Business Development, Competition Landscape and Emerging Trends with Focusing Key Players: Alcon, Novartis AG, Johnson & Johnson Vision Care, Carl Zeiss Meditec, HOYA Corporation

The global Monofocal IOLs market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.

VRX.TO : 30.80 (-3.33%)
JNJ : 131.36 (+0.63%)
STAA : 33.19 (+3.98%)
HOCPF : 74.0000 (-2.63%)
NVS : 89.47 (+1.00%)
CZMWF : 109.0000 (+0.93%)
Watch for Johnson&Johnson to Potentially Pullback After Gaining 1.46% Yesterday

Johnson&Johnson (NYSE:JNJ) traded in a range yesterday that spanned from a low of $131.95 to a high of $133.94. Yesterday, the shares gained 1.5%, which took the trading range above the 3-day high of...

JNJ : 131.36 (+0.63%)
Grenco Science and Vapium Announce Joint Venture to Introduce Accudose, a First-of-Its-Kind, Accurate Dosing Technology for Cannabis Consumption

Grenco Science, the leader in advanced technology cannabis vaporization, announces a joint venture with Vapium, the award-winning vaporization company and resident of Johnson & Johnson Innovation - JLABS...

JNJ : 131.36 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average.

See More Share

Trade JNJ with:

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Key Turning Points

2nd Resistance Point 132.28
1st Resistance Point 131.82
Last Price 131.36
1st Support Level 130.75
2nd Support Level 130.13

See More

52-Week High 148.99
Fibonacci 61.8% 138.30
Fibonacci 50% 134.99
Fibonacci 38.2% 131.69
Last Price 131.36
52-Week Low 121.00

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar